What is the prognosis for stage IV gastric cancer and what is the keystone first‑line chemotherapy regimen, including modifications for HER‑2‑positive, MSI‑high, or PD‑L1‑positive disease?

Stage IV Gastric Cancer: Prognosis and First-Line Chemotherapy

For stage IV gastric cancer, median overall survival ranges from 8–11 months with modern combination chemotherapy, and the keystone first-line regimen is a fluoropyrimidine plus platinum doublet, with mandatory addition of trastuzumab for HER2-positive disease, nivolumab or pembrolizumab for PD-L1 CPS ≥1, and consideration of triplet cytotoxic therapy only in highly selected patients with excellent performance status. 1

Prognosis

Overall Survival Expectations:

• Median survival with palliative combination chemotherapy is approximately 8–11 months, representing a 6.7-month improvement over best supportive care alone 2, 1
• The 5-year survival rate for stage IV disease remains approximately 7–10% 3
• Patients with metastases confined to nonregional lymph nodes only ("stage IV-nodal") demonstrate superior median survival of 10.5 months compared to single-organ metastases (8.0 months) or multi-organ metastases (5.7 months) 4

Prognostic Factors:

• Performance status is the most critical clinical determinant—chemotherapy should only be offered to patients with adequate functional status 2
• Number of metastatic sites: Single-site metastasis confers significantly better prognosis than multiple sites 5
• Peritoneal metastasis carries particularly poor prognosis (relative hazard 1.896) 3
• Hepatic metastasis independently worsens survival (hazard ratio 1.6) 6
• Lymphatic and venous invasion are adverse prognostic factors (relative hazards 1.736 and 1.481, respectively) 3
• Weight loss >5% at diagnosis significantly worsens prognosis (hazard ratio 1.96) 6

Keystone First-Line Chemotherapy Regimen

Mandatory Biomarker Testing Before Treatment Selection

All patients with stage IV gastric adenocarcinoma must undergo:

• HER2 testing (immunohistochemistry ± FISH) to determine trastuzumab eligibility 2, 1
• PD-L1 combined positive score (CPS) assessment to guide immunotherapy selection 2, 1
• MSI/dMMR testing (though specific MSI-high recommendations are not detailed in the provided evidence)

Treatment Algorithm by Biomarker Status

HER2-Positive Disease (10–15% of cases)

Preferred regimen: Fluoropyrimidine + oxaliplatin + trastuzumab ± pembrolizumab (if CPS ≥1) 1

Alternative regimen: Fluoropyrimidine + cisplatin + trastuzumab ± pembrolizumab (if CPS ≥1) 1

• The addition of trastuzumab to platinum-fluoropyrimidine doublet chemotherapy is mandatory (NCCN Category 1) and improves median overall survival from 11.1 to 13.8 months 2, 1
• Trastuzumab benefit is most pronounced in patients with IHC 3+ or IHC 2+/FISH-positive tumors 2

HER2-Negative Disease with PD-L1 CPS ≥1

Preferred regimen: Fluoropyrimidine + oxaliplatin + nivolumab (Category 1 for CPS ≥5) 2, 1

Alternative regimen: Fluoropyrimidine + oxaliplatin + pembrolizumab 2, 1

• Immunotherapy combined with chemotherapy is now standard first-line for PD-L1 CPS ≥1 1
• The evidence is strongest (Category 1) for nivolumab when CPS ≥5 1

HER2-Negative, PD-L1-Negative or Low CPS

Standard doublet regimen options:

1. EOX (epirubicin + oxaliplatin + capecitabine) – preferred in many centers 2, 1

   • Median overall survival 11.2 months 2
   • Eliminates need for central venous catheter 2
   • Reduced thromboembolism risk compared to ECF 2

2. ECX (epirubicin + cisplatin + capecitabine) – established alternative 2, 1

   • Non-inferior to ECF in the REAL-2 trial 2

3. ECF (epirubicin + cisplatin + 5-FU) – historical standard 2

   • Among the most active and well-tolerated regimens 2
   • Requires central venous access device 2

Triplet regimen (reserved for highly selected patients):

• DCF (docetaxel + cisplatin + 5-FU) or modified DCF 2, 1
  • Should only be used in patients with excellent performance status, high tumor burden, and ability to undergo frequent toxicity monitoring 1
  • Adds approximately 1 month overall survival benefit but significantly increases febrile neutropenia risk 2, 1
  • Two-drug regimens are preferred due to lower toxicity (NCCN Category 1) 1

Alternative doublet options:

• Irinotecan + 5-FU/leucovorin: similar activity to cisplatin-based regimens with better tolerability 2
• Taxane-based combinations (docetaxel or paclitaxel + platinum/fluoropyrimidine) 2

Key Chemotherapy Principles

Fluoropyrimidine Selection:

• Capecitabine and 5-FU are interchangeable without compromising efficacy 2, 1
• Capecitabine eliminates the need for central venous access and reduces thromboembolism 2
• S-1 (oral tegafur-based agent) is widely used in Asian populations but remains investigational in Western populations 1, 5

Platinum Selection:

• Oxaliplatin is preferred over cisplatin due to more favorable toxicity profile (reduced nephrotoxicity, ototoxicity, nausea) 2, 1
• The overall survival difference is modest (<1 month) 1

Anthracycline Role:

• Meta-analysis demonstrates significant benefit from adding epirubicin to platinum-fluoropyrimidine doublets 2
• The MAGIC trial showed epirubicin-containing ECF improved 5-year survival from 23% to 36.3% in the perioperative setting 2

Second-Line Therapy

After progression on first-line chemotherapy, monotherapy with:

• Paclitaxel (weekly preferred) 2, 1

• Docetaxel 2, 1

• Irinotecan (preferred after platinum failure due to better tolerability) 2, 1

• Second-line chemotherapy improves overall survival and quality of life compared to best supportive care, with median survival of 8–9 months in selected patients 2

• Irinotecan extends overall survival by approximately 1.6 months versus regimens without it 1

• Patients who progress >3 months after first-line may be re-challenged with the same regimen 2

Critical Pitfalls to Avoid

Do not offer chemotherapy to patients with:

• Poor performance status (ECOG ≥2) 2
• Significant comorbidities or organ dysfunction 2
• These patients should receive best supportive care alone 2

Do not routinely use triplet cytotoxic regimens:

• Reserve DCF/modified DCF only for patients with excellent performance status and high tumor burden who can tolerate frequent monitoring 1
• Two-drug combinations are the standard (Category 1) 1

Do not omit biomarker testing:

• HER2 testing is mandatory—missing HER2-positive disease denies patients a survival-improving targeted therapy 2, 1
• PD-L1 CPS testing is essential for immunotherapy selection 2, 1

Do not use cisplatin when oxaliplatin is available:

• Oxaliplatin provides equivalent efficacy with significantly better tolerability 2, 1

Do not continue chemotherapy indefinitely:

• Symptom-driven follow-up is recommended over intensive surveillance 2
• Radiological assessment should be performed at intervals to guide continuation or change of therapy 2

Special Considerations

Palliative radiotherapy:

• Hypofractionated radiotherapy is effective for symptomatic locally advanced disease causing bleeding, obstruction, or pain 2

Palliative gastrectomy:

• May be considered in highly selected patients who achieve excellent response to systemic therapy 2
• Retrospective data suggest palliative gastrectomy improves survival (hazard ratio 12 for no gastrectomy) 6
• However, resection of the primary tumor is not generally recommended in the palliative setting 2

Clinical trial enrollment:

• Should always be considered, especially for second-line therapy where no standard regimen exists 2